Malignant Cervical Neoplasm — Trials

Malignant Cervical Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 506
Recruiting: 280
Ph III recruiting: 34
Growth YoY: −11.9%
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: 22.7%
Trials / 1,000 deaths: 121.6 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (181)

clinicaltrialsPublishedShowing 1–34 of 34 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05256225	Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma	recruiting	Phase 3	360	National Cancer Institute (NCI)NIH	3	Sep 29, 2026	clinicaltrials
NCT07061977	Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer	recruiting	Phase 3	336	National Cancer Institute (NCI)NIH